Table 3:
Patient characteristics of cSCC subgroup
| ICI (n=24) | non-ICI (n=23) | ||
|---|---|---|---|
| Age, yr | 62.5 (55–71.3) | 62.7 (58–67) | |
| Female (%) | 1 (4.2) | 6 (23.1) | |
| Time from transplant to diagnosis, yr | 12 (4.7–17.4) | 11.1 (6.1–18.9) | |
| Stage at advanced diagnosis (%) | III (unresectable) | 3 (12.5) | 1 (4.3) |
| IV | 20 (83.3) | 22 (95.7) | |
| Unknown | 1 (4.2) | 0 (0) | |
| Baseline Cr, mg/dl | 1.45 (1.0–1.9) | 1.50 (1.0–1.9) | |
| Other cancer-directed therapy (%) | 15 (62.5) | 20 (87.0) | |
| ICI | |||
| Pembrolizumab (%) | 8 (33.3) | ||
| Nivolumab (%) | 2 (8.3) | ||
| Cemiplimab (%) | 10 (41.7) | ||
| Ipilimumab (%) | 1 (4.2) | ||
| Combination (%) | 3 (12.5) | ||
| Tumor response | |||
| CR (%) | 2 (8.3) | 1 (4.3) | |
| PR (%) | 6 (25) | 1 (4.3) | |
| SD (%) | 4 (16.7) | 3 (13.0) | |
| PD (%) | 10 (41.7) | *18 (78.3) | |
| Unknown (%) | 2 (8.3) | 0 (0) | |
| Number of immunosuppressants (%) | |||
| 0 | 1 (4.1) | 0 (0.0) | |
| 1 | 4 (16.7) | 6 (26.1) | |
| 2 | 15 (62.5) | 13 (56.5) | |
| 3 | 4 (16.7) | 4 (17.4) | |
| Rejection (%) | 9 (37.5) | 1 (4.3) | |
| Follow-up, months | 14.2 (10.7–26.3) | 9.7 (4.5–20.1) | |
Data are shown as median (IQR) and n (%).
cSCC; cutaneous squamous cell carcinoma, IQR; interquartile range, Cr; creatinine, ICI; immune checkpoint inhibitor, CR; complete response, PR; partial response, SD; stable disease, PD; progressive disease,
*
Includes 6 undetermined cases (SD vs PD). Other cancer-directed therapy includes chemotherapy and molecular-targeted therapy except for ICI.